Revenue
2016
2017
2018
2019
2020
ENDRA Life Sciences Inc. (NDRA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $6,174 | $351,622 | $515,582 |
| Gross profit | — | — | — | — | — | $0 | $0 | $6,174 | $178,840 | $279,704 |
| Research & development | $1.8M | $3.2M | $5.0M | $6.6M | $5.5M | $5.9M | $6.6M | $4.7M | $1.9M | $495,377 |
| Operating expenses | $5.8M | $10.8M | $10.5M | $13.2M | $11.5M | $11.5M | $10.8M | $9.0M | $4.8M | $2.1M |
| Operating income | −$5.8M | −$10.8M | −$10.5M | −$13.2M | −$11.5M | −$11.5M | −$10.8M | −$9.0M | −$4.6M | −$1.8M |
| EBITDAderived | −$5.7M | −$10.8M | −$10.4M | −$13.1M | −$11.4M | −$11.4M | −$10.8M | −$9.0M | −$4.6M | −$1.7M |
| Net income | −$7.0M | −$11.5M | −$10.1M | −$13.2M | −$11.2M | −$11.7M | −$13.3M | −$9.8M | −$5.4M | −$2.8M |
| Basic EPSper diluted share | -$8.93 | -$56.94 | — | -$4.56 | -$5.55 | -$0.63 | -$2.34 | -$2.17 | -$1.95 | -$3.84 |
| Diluted EPSper diluted share | -$8.93 | -$56.94 | -$2,766.85 | — | — | -$0.63 | -$2.34 | -$2.17 | -$1.95 | -$3.84 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 27, 2024Form 4/A | UBS Group AGOther | BuyCommon Stock · indirect | 0 | $0.00 | $0.00 | 146.0K |
| Aug 27, 2024Form 4 | UBS Group AGTenPercentOwner | BuyCommon Stock · indirect | 3.7K | $0.55 | $2.0K | 146.0K |